Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Online Tool Helps RA Patients Make Informed Decisions

Arthritis Care & Research  |  November 3, 2015

“Effective risk communication is an essential component of care for [rheumatoid arthritis] RA patients,” says Liana Fraenkel, MD, MPH, from Yale University School of Medicine, Section of Rheumatology, and colleagues.

The decision to escalate care for patients with RA can be difficult without adequate decision-making support and education, particularly with regard to initiating therapy with a biologic agent. In their most recent research, Dr. Fraenkel and colleagues assessed the value of a previously developed, Web-based interactive decision support tool and its ability to increase a patient’s objective and subjective knowledge, as well as values clarification and satisfaction with communication. The tool, which was developed with extensive patient and physician input, was also evaluated for the number of patients with the ability to make an informed choice to escalate care by going on a biologic agent after two weeks. The results were published in the November 2015 issue of Arthritis Care & Research.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

This eight-week, single-blind pilot trial included 125 patients with RA who were randomized into two groups: an intervention group using the online tool and a control group following the standard course of care. The intervention group was given access to the online tool and asked to review its content within two weeks. No limit was placed on how often the information was access. The control group received education and counseling from an experienced nurse, which is the current standard of care.

The Results
“We found that patients viewing an interactive Web-based tool designed to effectively inform patients about the risks and benefits associated with adding a biologic agent in order to control disease activity resulted in significant improvements in objective knowledge, subjective knowledge and values clarity,” write the authors.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

No measurable increase in objective or subjective knowledge was demonstrated in the control group. After two weeks, a greater percentage of the intervention group met the criteria for making an informed choice: 32% vs. 13% for the control group. According to the researchers, “This difference remained statistically significant (37% vs. 11%; P=0.001) when all individuals, whether or not they had escalated treatment, were included in the sample. … Among those escalating care, the proportion defined as making an informed choice was significantly greater among those randomized to the intervention than the control arm.”

In this study, 90% of treatment changes resulted in the initiation of a biologic. Because of this high rate, researchers say they were unable to evaluate whether or not decision support changes treatment escalation rates. “Future studies conducted in clinical settings with average to lower than expected escalation rates will help determine whether the benefits of the tool extend beyond improving knowledge and values clarification,” they write.

Going forward, researchers note the importance of adapting the tool for mobile devices to meet the demand “to provide health-related decision support on … readily available platforms.”

Additionally, the researchers conclude, “Future efforts will be required to ensure that the information is updated as needed, and that the tool is easily accessible, ideally via a link through trusted websites already familiar to rheumatologists.”

Read the full article.

Fraenkel L, Matzko CK, Webb DE, Oppermann B, Charpentier P, Peters E, Reyna V, Newman ED. Use of decision support improves knowledge, value clarification and informed choice in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2015 Jul 20. doi: 10.1002/acr.22659. [Epub ahead of print]

Page: 1 2 | Multi-Page
Share: 

Filed under:ConditionsResearch RheumRheumatoid ArthritisTechnology Tagged with:Arthritis Care & Researchbiologic drugsonline educationpatient communicationpatient education

Related Articles

    Are You Informed About Informed Consent?

    May 1, 2008

    Physicians walk a fine line between informed consent and patient trust

    MDGRPHaCS / shutterstock.com

    The ACR Releases an Updated Treatment Guideline for Rheumatoid Arthritis

    June 14, 2021

    In early June, the ACR released an updated guideline on the management of rheumatoid arthritis, which includes new recommendations for specific high-risk groups.1 The guideline includes 44 recommendations—seven of which are strong and 37 conditional. It underscores the role of methotrexate as a cornerstone therapy and emphasizes minimizing glucocorticoids, when possible. Guideline Development Process At…

    Why & How to Pursue Shared Decision Making with Your Patients

    June 21, 2018

    Hurca / shutterstock.com Over the past several decades, the medical community has been moving toward a model of shared decision making. In addition to its ethical advantages, shared decision making potentially yields such benefits as improved medical adherence and better health outcomes. With the proliferation of treatment options and changes in the larger culture, shared…

    A Conversation with Rheumatology Research Foundation VP Liana Fraenkel, MD, MPH

    May 5, 2023

    Dr. Fraenkel Liana Fraenkel, MD, MPH, likes to fix things, and the dynamic and challenging field of rheumatology always has room for improvement. That mindset has led her down some interesting paths as a researcher and healthcare provider, and as vice president of the Rheumatology Research Foundation. Dr. Fraenkel was a rheumatologist and researcher at…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences